Protalix BioTherapeutics (PLX) Reports Q2 Loss of $0.11/Share

August 8, 2016 4:56 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), versus ($0.05) reported last year. Revenue for the quarter came in at $1.77 million, versus $1.34 million reported last year.

For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment